Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The next big share price gain should come shortly when Leo announces the conclusion of Kevetrin Phase 1. Especially if the announcement comes with some efficacy detail.
wild4ctix Member Level Wednesday, 06/03/15 09:37:15 PM
Re: loanranger post# 106388
Post # of 113190
Hahaha. Didn't read the other two responses from Leo until now as I was traveling from Dallas. But just to make it a Trifecta, below is a response he sent me today as well. I also inquired after I received the below response about a journal article about K and he responded " it will happen "....but below is his first response ( for the third time " hahaha
Hi,
I will be following up tomorrow with NASDAQ and ask for our status.
Brilacidin- Yes, we announced a date had been set for the end of June.
We will be giving updates regularly. I too am anxious for things to speed up.
Over the next 2-3 months we can expect
Kevetrin concluding/ conclusion Phase 1.
Brialcidin FDA meeting for Phase 3 update
Brilacidin OM info on trial
Psoriasis
NASDAQ
Lots more
Thank you.
Leo Ehrlich | CEO |
Anavex did Dr. Vamvakides a huge favor by taking on an unproven drug and funding the trials.
Vamvakides owes a huge debt of gratitude to Anavex.
Fabulous week for Anavex -
Over the top trial data. Much better, I'm sure, than any of us expected.
The trumped up "patent issue" was blown out of the water.
GL,
Longs
Doktornolittle, perhaps you haven't read this -
DD - Updated Collection Of Recent Articles And Videos With The Most Recent First:
Go to Anavex.com for press releases and more info on the Company
https://au.news.yahoo.com/video/watch/29015798/new-pills-offer-hope-for-alzheimers-sufferers/#page1
"It's like being in the dark and someone switched the light on."
http://www.heraldsun.com.au/news/victorians-first-to-trial-breakthrough-brain-booster-pill/story-fni0fiyv-1227453139615
A PILL to treat Alzheimer’s disease is four times more effective than the current treatment in boosting the brain power of patients.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.
http://thestockradio.com/otcqx-avxl-anavex-life-sciences-corp-ceo-pres-christopher-missling-2050.html
http://www.anavex.com/
Corporate Presentation - Spring 2015
http://www.endevr.com/dementia/New-drug-might-help-prevent-slow-or-reverse-Alzheimer-s
Findings in a recent peer-reviewed scientific journal reveals that our lead drug, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
Yes, I'll do it along with the earlier trial article.
AVXL ... $0.75 ... Alzheimer Disease ... No good drug available so far
Possible life changing stock. Phase 2A Data on the first 12 patients reported 7/22.
“This is the first time the investigational drug ANAVEX 2-73 has been administered to Alzheimer’s patients. In addition to the positive EEG/ERP P300 biomarker signal, the feedback we’ve had so far is that patients and care providers have noticed both cognitive and functional improvement, increased alertness, improvement in activities of daily living, greater organization and a requirement for less prompting,” said study’s principal investigator Dr. Stephen Macfarlane, FRANZCP, Associate Professor and Director of Aged Psychiatry at The Alfred Hospital. “Subsequent to the positive initial feedback, we are applying to expand the extension period from 26 weeks to 52 weeks at the request of the participants.”
http://www.anavex.com/?post_type=news&p=1491
I'm already looking forward to the next data release.
A couple of statements from Wednesday's PR -
additional clinical data of the trial will be presented at future medical meetings.
As of today, we have enrolled two-thirds of the patients.
Medical meetings Dr. Missling has attended in the past year -
9/10/14 - Rodman & Renshaw 16th Annual Global Investment Conference
11/12/14 - SeeThruEquity Fall Microcap Investor Conference
11/14/14 - CNS Summit 2014
1/12/15 - Biotech Showcase 2015
1/13/15 - 8th Annual OneMedForum
2/10/15 - 17th Annual BIO CEO & Investor Conference
3/11/15 - 27th Annual ROTH Conference
3/17/15 - The Physiopathology of Sigma-1 Receptors’ symposium
3/22/15 - 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2015)
4/23/15 - World Orphan Drug Congress
5/27/15 - 2015 Marcum Microcap Conference
7/22/15 - Alzheimer’s Association International Conference® 2015 (AAIC)
Smart Girl!!!
10b5-1 trading plan -
https://www.mystockoptions.com/faq/index.cfm/catID/8697D129-C7BB-4896-8D462B468949D1BE/objectID/EA9AC5F8-08BE-4626-BC50A9FDD719DEA5
Missling set up his plan on June 3rd. Well ahead of today's press release.
I'll tell you why your technical charting is off the mark.
You spent weeks cheerleading for a dive to the upper .20s to low .30s. Now you are back with more fortune telling.
The price will move according to supply and demand, in spite of how many lines and arcs you draw.
AVXL Share Structure - Fully Diluted - 143,892,854
(by my calculations)
5-14-15 ... 77,243,580 common stock outstanding
3-31-15 ... 78,965,632 share purchase warrants
3-31-15 ... 3,170,000 options
The 77,243,580 shares O/S on 5-14-15 include the 15,486,358 warrants exercised as a result of the S-1 below.
This prospectus relates to the sale or other disposition from time to time of shares of common stock, par value $0.001 per share, of Anavex Life Sciences Corp., a Nevada corporation, by certain of our security holders (the “Selling Security Holders”). The shares offered for resale by this prospectus include 15,486,358 shares of the Company’s common stock issuable upon exercise of the Series A Warrants (the “Series A Warrants”) issued by the Company on March 18, 2014 which may be exercisable at a price of $0.30 per share.
It would make sense to me that the number of warrants has dropped by 15,486,358 to 63,479,274.
AVXL Share Structure -
5-14-15 ... 77,243,580 common stock outstanding
3-31-15 ... 78,965,632 share purchase warrants
3-31-15 ... 3,170,000 options
The 77,243,580 shares O/S on 5-14-15 include the 15,486,358 warrants exercised as a result of the S-1 below.
This prospectus relates to the sale or other disposition from time to time of shares of common stock, par value $0.001 per share, of Anavex Life Sciences Corp., a Nevada corporation, by certain of our security holders (the “Selling Security Holders”). The shares offered for resale by this prospectus include 15,486,358 shares of the Company’s common stock issuable upon exercise of the Series A Warrants (the “Series A Warrants”) issued by the Company on March 18, 2014 which may be exercisable at a price of $0.30 per share.
It would make sense to me that the number of warrants has dropped by 15,486,358 to 63,479,274.
Fully Diluted - AVXL Share Structure -
5-14-15 ... 77,243,580 common stock outstanding
3-31-15 ... 78,965,632 share purchase warrants
3-31-15 ... 3,170,000 options
The 77,243,580 shares O/S on 5-14-15 include the 15,486,358 warrants exercised as a result of the S-1 below.
This prospectus relates to the sale or other disposition from time to time of shares of common stock, par value $0.001 per share, of Anavex Life Sciences Corp., a Nevada corporation, by certain of our security holders (the “Selling Security Holders”). The shares offered for resale by this prospectus include 15,486,358 shares of the Company’s common stock issuable upon exercise of the Series A Warrants (the “Series A Warrants”) issued by the Company on March 18, 2014 which may be exercisable at a price of $0.30 per share.
It would make sense to me that the number of warrants has dropped by 15,486,358 to 63,479,274.
Fully Diluted - 143,892,854
I have to think that Anavex will be the beneficiary of loads of good press in the coming weeks proclaiming them as the standout at the Alzheimer’s Association International Conference® 2015 (AAIC).
Now that the first data has been reported, hopefully, Missling will update trial data frequently.
That's the key -
You're the only one talking about Aricept patents.
Anavex response in regard to "patent issue" -
Dear Mr. .....,
I am providing you with an addendum regarding your patent-related questions about Anavex Life Sciences Corp. (OTCQX: AVXL).
Regarding your question about Dr. Vamvakides’ contractual obligations, under the “2012 Addendum to the Contract for the Transfer of a Patent Invention and Scientific Collaboration” dated January 11, 2013, paragraph 3.4 states that in addition to rights already conveyed, Dr. Vamvakides conveys all rights of every nature with particular reference to the patent rights in the Project. The Project is the subject matter of the patent applications at issue.
Regarding your question about the time frame involved to obtain the required assignments, an assignment document can be obtained at any time. As noted earlier, Anavex anticipates resolving matters with Dr. Vamvakides.
Thank you for your interest in our client Anavex Life Sciences Corp. (OTCQX: AVXL).
In response to your question, Dr. Vamvakides is under contractual obligations to assign the intellectual property to Anavex. Anavex anticipates obtaining the required assignments in good time. On October 20, 2014 Anavex filed a provisional patent application USSN 62/065833. The quoted language relates to Anavex filed patent applications. As noted above, Dr. Vamvakides is under contractual obligations to assign the intellectual property to Anavex. Anavex anticipates obtaining any required documents in good time. Anavex believes that any issues with Dr. Vamvakides will be amicably resolved and will not materially impact Anavex’s programs.
Please do not hesitate to contact our office if we can be of further assistance.
Sincerely,
Adam Bello
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113268971&txt2find=contractual|obligation
Yes, I read further just now -
About the ANAVEX 2-73 Phase 2a Study
The ongoing, multicenter Phase 2a adaptive trial of ANAVEX 2-73 in both male and female mild-to-moderate Alzheimer’s patients seeks to enroll 32 patients. It started in January 2015 and the first 12 patients, most who are also taking donepezil, have completed PART A of the two-part trial. Lasting up to 36 days for each patient, PART A is a simple randomized, open-label, two-period trial with an on-off-on not-yet-optimized dosing regimen to assess bioavailability, and cross-over between oral (30mg/50mg) and IV (3mg/5mg) administration. Event-related potentials (EEG/ERP) are used to assess cognitive effects and optimize dosing of ANAVEX 2-73. PART B is an open-label extension for an additional 26 weeks, with daily oral dosing so as to establish a longer drug effect.
Weren't these patents already on Aricept?
Fabulous news!!!
bernardc, thanks for sharing that info!
Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
(Also check "About Cellceutix" below for Prurisol trial start info)
Company Reports Successful End-of-Phase 2 Meeting With FDA
BEVERLY, MA--(Marketwired - July 20, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has agreed to advancing brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
During a recently held End-of-Phase 2 Meeting, Cellceutix and the FDA discussed safety and efficacy data that support advancement into phase 3, as well as the basic elements of a phase 3 program. The planned phase 3 program would include two phase 3 ABSSSI studies, as required by FDA Guidance. In addition, the first study would include an interim analysis after a portion of the patients has been enrolled. This would provide an early assessment of both safety and efficacy. As part of the agreement, the Company would submit a Pediatric Study Plan (PSP) within 60 days of the End-of-Phase 2 Meeting.
Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer and leader of the team that met with the FDA, was pleased with the outcome of the meeting. "This was a collaborative meeting, and the FDA was extremely helpful in providing guidance on our clinical development program in ABSSSI. The plan for an interim analysis makes sense, as this is a brand new class of antibiotics."
Brilacidin is the lead compound in a new class of antibiotics known as the defensin-mimetics. These compounds mimic the host defense proteins of the innate immune system, and therefore, have both antibacterial and immunomodulatory properties. Brilacidin has been administered intravenously in over 400 subjects in phase 1 and phase 2, and is currently being evaluated in a phase 2 study as a topical rinse for the prevention and treatment of oral mucositis in cancer patients.
Brilacidin was granted Qualified Infectious Disease Product (QIDP) designation by the FDA in November 2014. The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act for the purpose of encouraging development of new antimicrobial drugs to treat serious and life-threatening infections. Receiving QIDP designation means that brilacidin is now eligible for additional FDA incentives, including Fast Track designation and Priority Review for clinical development, and a five-year extension of market exclusivity.
Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.CRfqSmmY.dpbs
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is being readied for a Phase 2 trial scheduled to begin July 28, 2015. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Dr De's Opening Thoughts: Alzheimer's
I was working on an article on Anavex (OTCQX:AVXL) and coincidentally, two Alzheimer's related events occurred lately. One is an FDA whitepaper that not only says that AD is one of the least developed areas in medicine and therapy today, but also says that amyloid beta plaque reduction therapies are not working, and it is time to look at other options. The other is the Alzheimer's Association International Conference (AAIC) held at Washington DC between July 18-25, which is the world's largest forum for the dementia research community.
http://seekingalpha.com/article/3337595-premarket-biotech-digest-alzheimers-conference-gilead-new-odd-axovant-pops?isDirectRoadblock=false&uprof=
NP, I think we all have a lot to learn.
It will be interesting to see what time the PR comes out Wednesday Morning. The people in the conference hall will be able to see the poster before 9:30 unless the poster is covered, which I doubt.
To keep some people from having early knowledge of what could be game changing information, the PR should be released before the conference hall is open to anybody.
I know that if I lived in the D.C. area, I would go to the conference early and try to get the scoop. Possibly, before a PR is released.
Most everyone's shares are held in street name. For instance, Fidelity would count as 1 share holder even though ~200 Fidelity customers have AVXL in their accounts.
DEFINITION of 'In Street Name'
A brokerage account where the customer's securities and assets are held under the name of the brokerage firm, rather than the name of the individual who purchased the security or asset. Although the name on the certificate is not that of the individual, they are still listed as the real and beneficial owner and have the rights associated with the security.
INVESTOPEDIA EXPLAINS 'In Street Name'
It is more convenient for brokers to hold securities in street name due to the complexity of tracking each stock certificate to each individual. Almost all brokers hold securities electronically and all securities in a brokers name comprise their inventory. Any time a client needs to buy or sell stocks, the broker is readily able to allocate a portion of their inventory as required.
If brokers were to hold an inventory of paper securities, securities transactions would take more time. For example, if a client would like to sell their certificates, the broker would have to find the exact stock certificates owned by the client and send those securities back to the issuing company who would then change the names on the securities to that of the new owners.
Read more: http://www.investopedia.com/terms/i/instreetname.asp#ixzz3gN8L6auN
Follow us: @Investopedia on Twitter
OK, according to Tremors, Missling has been awarded 3,000,000 shares total for achieving 3 milestones. This 3mm plus the 2mm options puts Missling at 5mm shares.
There has been no Form 4 stating that Missling exercised the options. That's more important to know than how the 5mm are reported.
The latest milestone achieved must have been come after the Lincoln Park S-1 was declared effective. The original Lincoln Park S-1, back in 2013, never made it to effective status, apparently, or there would have been no need to file it again.
It all depends on if there is ground breaking news on that poster. Nearly all posters are blah, blah, nothing new.
We all know that AVXL had intended to release the first patient data in September and made a last minute decision to present at the conference. At the Marcum Conference on May 27th, the planned data release was still in September.
Was their timing too late to present orally?
Had Missling's options been exercised a Form 4 would have been filed. The 2,000,000 options are lumped into the 3,000,000 vested shares.
Form 4 filings state the changes to an insider's holdings when they occur. The Form 4 includes purchases and sales as well as exercise of options, disposition by gift, or other transactions.
On 7/1/15 Missling had 3,009,000 shares beneficially owned -
Explanation of Responses:
( 1) The purchases reported in this Form 4 were effected pursuant to a Rule 10B5-1 trading plan adopted by the reporting person on June 3, 2015.
( 2) Includes 2,000,000 stock options that have vested and 1,000,000 shares of restricted common stock that have vested pursuant to the achievement of certain objectives. Does not include 3,000,000 shares of restricted common stock that vest pursuant to the achievement of certain objectives.
http://ih.advfn.com/p.php?pid=nmona&article=67542365
On 7/14/15 Missling had 4,012,000 shares beneficially owned -
Explanation of Responses:
( 1) The purchases reported in this Form 4 were effected pursuant to a Rule 10B5-1 trading plan adopted by the reporting person on June 3, 2015.
( 2) Includes 4,000,000 shares of restricted common stock, 3,000,000 shares of which have vested pursuant to the achievement of certain objectives.
http://ih.advfn.com/p.php?pid=nmona&article=67709452
I second that -
Cellceutix mentioned briefly today in the Premarket Biotech Digest -
http://seekingalpha.com/article/3330265-premarket-biotech-digest-lure-of-startups-gerons-short-squeeze-new-odds?isDirectRoadblock=false&uprof=
This is a good daily heads-up on what is happening in the biotech sector.
Just look at yourself for the answer -
The Spring 2015 Presentation tells us (see bold)-
Page 26 -
PHASE 2a STUDY
ANAVEX 2-73 Dose A-E
ANAVEX 2-73 Dose A-E + Donepezil
No. of Patients: 32 mild-to-moderate AD patients
No. of Sites: Up to 7 sites
Allocation: Randomized
Duration: PART A: 36-days, PART B: 3-month and 6-month data analyses Endpoints: Safety Bioavailability Exploratory cognitive efficacy (EEG/ERP, MMSE, Cogstate and ADSC-ADL) Exploratory add-on therapy to AD standard of care
Efficient design embraces both adaptive trial features and population pharmacokinetics - Minimizes both timelines and cost
Captures all relevant information for a larger Phase 3 study
Page 31 -
Start Phase 2/3 study after Phase 2a
I've been in since the end of April. I loaded up at .35 average.
Yes, this is the study plan -
Corporate Presentation Spring 2015
http://www.anavex.com/
Page 26
No. of Patients: 32 mild-to-moderate AD patients
No. of Sites: Up to 7 sites
Allocation: Randomized
Duration: PART A: 36-days, PART B: 3-month and 6-month data analyses
Endpoints: Safety Bioavailability Exploratory cognitive efficacy (EEG/ERP, MMSE, Cogstate and ADSC-ADL) Exploratory add-on therapy to AD standard of care
I am in the camp that believes the data will be good - excellent.
I think Anavex has data on Part A and the 3 month portion of Part B.
Duration: PART A: 36-days, PART B: 3-month and 6-month data analyses
Good data will point to 2-73 becoming a platform drug for Central Nervous System diseases including Alzheimer Disease.
I'm guessing $1.50 - $2.00 end of month. Much higher by end of year.
Yup, there will be more selling and more buying coming up until the Company is bought out by Big Pharma.
Way to go, Jockimo!!!
Anavex 2-73 showed excellent results after only 2 months in mice. CEO Missling may tell us on the 22nd that the same is happening in humans. Fingers crossed!
Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer’s
Data Presented at Society for Neuroscience 2013 Annual Meeting
New York, NY — November 12, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is pleased to announce that new study data showed ANAVEX 2-73 to be effective in counteracting the progression of Alzheimer’s disease under chronic treatment in a transgenic mouse model of Alzheimer’s, named Tg2576. The new data was presented by Tangui Maurice, PhD, CNRS Research Director at the University of Montpellier and INSERM, at the Society for Neuroscience 2013 Annual Meeting, running November 9-13, 2013 in San Diego, California.
10-month-old Tg2576 mice, both female and male, were treated with ANAVEX 2-73, which was administered orally on a daily basis for two months. Results showed that ANAVEX 2-73 significantly alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working memory (spontaneous alternation in a Y-maze) and long-term spatial reference memory (place learning in a water maze). The treatment also showed a statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers.
ANAVEX 2-73 demonstrated to be effective on functional responses and biochemical markers of the toxicity developed in Tg2576 mice. Interestingly, the compound only marginally decreased soluble amyloid-beta brain contents. Since many therapeutic strategies based on lowering amyloid-beta have failed, it is quite possible that amyloid-beta reduction does not correlate directly with disease improvement.
Tangui Maurice, PhD, said, “These observations suggest that ANAVEX 2-73 induces a strong neuroprotective effect that is apparently amyloid-beta independent. The data also confirms the efficacy of the mixed muscarinic cholinergic and sigma-1 receptor agonist in a chronic transgenic mouse model of Alzheimer’s. The compound may enable effective brain protection during the most aggressive phase of the disease pathology.”
Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, said, “Alzheimer’s is a complex disease driven by multiple factors. These findings support the theory that a further “upstream” therapeutic intervention to rescue synaptic dysfunction directly might be more promising than manipulating “downstream” amyloid-beta functionality, given the complex role of amyloid-beta in neuronal physiology. The new study supports ANAVEX 2-73’s therapeutic potential through its moderate mixed muscarinic and sigma-1 agonist features and represents another potential validation for a further path into clinical trials.”
The poster, entitled “Chronic treatment with the tetrahydrofuran derivative ANAVEX 2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer’s disease model” was co-authored by Valentine Lahmy, PharmD, and Vanessa Villard, PhD, Amylgen. The full poster is available on the Anavex website at anavex.com/publications.html.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer. ANAVEX 2-73, a drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. Anavex is a publicly traded corporation quoted as AVXL.
AVXL Share Structure -
5-14-15 ... 77,243,580 common stock outstanding
3-31-15 ... 78,965,632 share purchase warrants
3-31-15 ... 3,170,000 options
The 77,243,580 shares O/S on 5-14-15 include the 15,486,358 warrants exercised as a result of the S-1 below.
This prospectus relates to the sale or other disposition from time to time of shares of common stock, par value $0.001 per share, of Anavex Life Sciences Corp., a Nevada corporation, by certain of our security holders (the “Selling Security Holders”). The shares offered for resale by this prospectus include 15,486,358 shares of the Company’s common stock issuable upon exercise of the Series A Warrants (the “Series A Warrants”) issued by the Company on March 18, 2014 which may be exercisable at a price of $0.30 per share.
It would make sense to me that the number of warrants has dropped by 15,486,358 to 63,479,274.
Fully Diluted - 143,892,854
Anavex filed an S-1 in March. Some, or most, of the selling you are seeing could be related to warrant exercise and sale. Volume has been excellent lately and hopefully this overhang is winding down quickly. Last week saw the highest volume in Company history with over 17,000,000 shares traded.
This prospectus relates to the sale or other disposition from time to time of shares of common stock, par value $0.001 per share, of Anavex Life Sciences Corp., a Nevada corporation, by certain of our security holders (the “Selling Security Holders”). The shares offered for resale by this prospectus include 15,486,358 shares of the Company’s common stock issuable upon exercise of the Series A Warrants (the “Series A Warrants”) issued by the Company on March 18, 2014 which may be exercisable at a price of $0.30 per share.
http://www.sec.gov/Archives/edgar/data/1314052/000106299315001191/forms1.htm
Good to hear that you are still buying. The unexpected early patient data report on July 22nd, at the Alzheimer’s Association International Conference® 2015 (AAIC), bodes well for the future.
If the computer simulation model is correct, those who bought at $5.00 in 2008 will look like geniuses soon enough.
Anavex Reports Predicted Clinical Effect for Anavex 2-73 in Computer Simulation Model of Alzheimer's Disease
Study Presented at CNS Summit 2013 Suggests ANAVEX 2-73 Will Have Clinically Detectable and Meaningful Effect in Alzheimer’s Disease, Especially When Combined With Aricept®
http://www.anavex.com/?post_type=news&p=870
House Approves Roskam Legislation to Combat Superbugs
http://roskam.house.gov/media-center/press-releases/house-approves-roskam-legislation-to-combat-superbugs